Affiliation:
1. Department of Gastrointestinal Medical Oncology National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital Tianjin China
2. Department of Cancer Center Peking Union Medical College Hospital, Chinese Academy of Medical Sciences Beijing China
Abstract
AbstractThis article summarizes the drug therapy progress of advanced hepatocellular carcinoma, biliary tract cancer, and pancreatic cancer in 2022, including chemotherapy, molecular targeted therapy, and immunotherapy, to provide reference information for current clinical treatment and future clinical research, and to better improve prognosis and quality of life in patients with hepatobiliary and pancreatic cancer.
Subject
Pharmacology (medical),Cancer Research,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Drug Discovery,Oncology
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献